Discovering the global burden of low vision, PlenOptika’s founders determined to design a solution that could provide better eye care for everyone, regardless of their circumstances and access to health care. The company has strong research and development relationships with institutions and agencies around the world, including the Aravind Eye Hospital (India), the Regional Government of Madrid (Spain), the National Institutes of Health, and the Massachusetts Institute of Technology—where our technology was invented and the first prototypes were designed. Based in Boston, Massachusetts, we have offices in Madrid and Singapore, and we’re proud to count among our board and advisors some of the world’s leading experts in optical science, clinical eye care, and business strategy.
Peer-reviewed research publications confirm our technology’s accuracy. Our research has been published in BMJ Open Ophthalmology, Optometry and Vision Science, Investigative Ophthalmology & Visual Science, and Annual Review of Biomedical Engineering. Highlights from our research show there was no statistically significant difference in the preferences for eyeglasses derived from subjective refraction versus those from QuickSee autorefraction, and that QuickSee provides measurements that agree more closely with subjective refraction than other handheld autorefractors.
PlenOptika and QuickSee have been recognized internationally by Essilor, ASME, Indo-US Science Technology Forum Endowment Fund, the Hult Prize, Beazley Designs of the Year, and MassChallenge and many others. We have been covered by Bloomberg Businessweek, MIT News, Vision Monday, FastCompany, the Boston Globe and other news outlets.